Delay in breast cancer treatments during the first COVID-19 lockdown. a multicentric analysis of 432 patients
- Vanni G.
- Tazzioli G.
- Pellicciaro M.
- Materazzo M.
- Paolo O.
- Cattadori F.
- Combi F.
- Papi S.
- Pistolese C. A.
- Cotesta M.
- Santori F.
- Caspi J.
- Chiaravalloti A.
- Muscoli S.
- Lombardo V.
- Grasso A.
- Caggiati L.
- Raselli R.
- Palli D.
- Altomare V.
- D'Angelillo R. M.
- Palombi L.
- Buonomo O. C.
Publication date
January 2020
DOI Publisher
Anticancer Research USA Inc. Language
EnglishAbstract
Background/Aim: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation. Patients and Methods: All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group. Results: A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown
Add to ORKG